Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 122

Similar articles for PubMed (Select 22157713)

1.

Infectious complications in kidney-transplant recipients desensitized with rituximab and intravenous immunoglobulin.

Kahwaji J, Sinha A, Toyoda M, Ge S, Reinsmoen N, Cao K, Lai CH, Villicana R, Peng A, Jordan S, Vo A.

Clin J Am Soc Nephrol. 2011 Dec;6(12):2894-900. doi: 10.2215/CJN.03710411.

2.

Increase of infectious complications in ABO-incompatible kidney transplant recipients--a single centre experience.

Habicht A, Bröker V, Blume C, Lorenzen J, Schiffer M, Richter N, Klempnauer J, Haller H, Lehner F, Schwarz A.

Nephrol Dial Transplant. 2011 Dec;26(12):4124-31. doi: 10.1093/ndt/gfr215. Epub 2011 May 28.

3.

Polyomavirus BK viremia in kidney transplant recipients after desensitization with IVIG and rituximab.

Barbosa D, Kahwaji J, Puliyanda D, Mirocha J, Reinsmoen N, Lai CH, Villicana R, Peng A, Jordan SC, Vo A, Toyoda M.

Transplantation. 2014 Apr 15;97(7):755-61. doi: 10.1097/01.TP.0000437671.78716.f3.

PMID:
24686425
4.

Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation.

Vo AA, Peng A, Toyoda M, Kahwaji J, Cao K, Lai CH, Reinsmoen NL, Villicana R, Jordan SC.

Transplantation. 2010 May 15;89(9):1095-102. doi: 10.1097/TP.0b013e3181d21e7f.

PMID:
20110854
5.

Benefits of rituximab combined with intravenous immunoglobulin for desensitization in kidney transplant recipients.

Vo AA, Choi J, Cisneros K, Reinsmoen N, Haas M, Ge S, Toyoda M, Kahwaji J, Peng A, Villicana R, Jordan SC.

Transplantation. 2014 Aug 15;98(3):312-9. doi: 10.1097/TP.0000000000000064.

PMID:
24770617
6.

Efficacy, outcomes, and cost-effectiveness of desensitization using IVIG and rituximab.

Vo AA, Petrozzino J, Yeung K, Sinha A, Kahwaji J, Peng A, Villicana R, Mackowiak J, Jordan SC.

Transplantation. 2013 Mar 27;95(6):852-8. doi: 10.1097/TP.0b013e3182802f88.

PMID:
23511212
7.

Clinical outcome in patients with chronic antibody-mediated rejection treated with and without rituximab and intravenous immunoglobulin combination therapy.

Chung BH, Kim Y, Jeong HS, Hong YA, Choi BS, Park CW, Choi YJ, Kim YS, Yang CW.

Transpl Immunol. 2014 Sep;31(3):140-4. doi: 10.1016/j.trim.2014.08.005. Epub 2014 Aug 29.

PMID:
25179826
8.

Immunologic parameters and viral infections in patients desensitized with intravenous immunoglobulin and rituximab.

Ge S, Pao A, Vo A, Deer N, Karasyov A, Petrosyan A, Kahwaji J, Lukovsky M, Chai NN, Aguiluz A, Mirocha J, Jordan SC, Toyoda M.

Transpl Immunol. 2011 Apr 15;24(3):142-8. doi: 10.1016/j.trim.2010.11.006. Epub 2010 Nov 28.

PMID:
21122815
9.

Combined use of rituximab and plasmapheresis pre-transplant increases post-transplant infections in renal transplant recipients with basiliximab induction therapy.

Chung BH, Yun JT, Ha SE, Kim JI, Moon IS, Choi BS, Park CW, Kim YS, Yang CW.

Transpl Infect Dis. 2013 Dec;15(6):559-68. doi: 10.1111/tid.12135. Epub 2013 Sep 9.

PMID:
24011062
10.

Successful kidney transplantation after desensitization using plasmapheresis, low-dose intravenous immunoglobulin, and rituximab in highly sensitized patients: a single-center experience.

Jin MK, Cho JH, Kwon O, Hong KD, Choi JY, Yoon SH, Park SH, Kim YL, Kim CD.

Transplant Proc. 2012 Jan;44(1):200-3. doi: 10.1016/j.transproceed.2011.11.040.

PMID:
22310614
11.

Evaluation of two different preconditioning regimens for ABO-incompatible living kidney donor transplantation. A comparison of splenectomy vs. rituximab-treated non-splenectomy preconditioning regimens.

Tanabe K, Ishida H, Shimizu T, Omoto K, Shirakawa H, Tokumoto T.

Contrib Nephrol. 2009;162:61-74. doi: 10.1159/000170813. Epub 2008 Oct 31.

PMID:
19001814
12.

Evaluation of low-dose rituximab induction therapy in living related kidney transplantation.

Takagi T, Ishida H, Shirakawa H, Shimizu T, Tanabe K.

Transplantation. 2010 Jun 27;89(12):1466-70. doi: 10.1097/TP.0b013e3181dc0999. Erratum in: Transplantation. 2010 Sep 15;90(5):589.

PMID:
20559108
13.

Infectious complications in living-donor kidney transplant recipients undergoing multi-modal desensitization.

Turza KC, Shafique M, Lobo PI, Sawyer RG, Keith DS, Brayman KL, Agarwal A.

Surg Infect (Larchmt). 2014 Jun;15(3):182-6. doi: 10.1089/sur.2012.231. Epub 2014 Apr 28.

PMID:
24773230
14.

Vienna experience of ABO-incompatible living-donor kidney transplantation.

Haidinger M, Schmaldienst S, Körmöczi G, Regele H, Soleiman A, Schwartz D, Derfler K, Steininger R, Mühlbacher F, Böhmig GA.

Wien Klin Wochenschr. 2009;121(7-8):247-55. doi: 10.1007/s00508-009-1161-3.

PMID:
19562281
15.

Polyomavirus BK Viremia in Kidney Transplant Recipients After Desensitization With IVIG and Rituximab.

Barbosa D, Kahwaji J, Puliyanda D, Mirocha J, Reinsmoen N, Lai CH, Villicana R, Peng A, Jordan SC, Vo A, Toyoda M.

Transplantation. 2013 Nov 21. [Epub ahead of print]

PMID:
24270097
16.

The effect of combination therapy with rituximab and intravenous immunoglobulin on the progression of chronic antibody mediated rejection in renal transplant recipients.

An GH, Yun J, Hong YA, Khvan M, Chung BH, Choi BS, Park CW, Choi YJ, Kim YS, Yang CW.

J Immunol Res. 2014;2014:828732. doi: 10.1155/2014/828732. Epub 2014 Jan 29.

17.

Rituximab and intravenous immune globulin for desensitization during renal transplantation.

Vo AA, Lukovsky M, Toyoda M, Wang J, Reinsmoen NL, Lai CH, Peng A, Villicana R, Jordan SC.

N Engl J Med. 2008 Jul 17;359(3):242-51. doi: 10.1056/NEJMoa0707894.

18.

Kidney transplantation after desensitization in sensitized patients: a Korean National Audit.

Huh KH, Kim BS, Yang J, Ahn J, Kim MG, Park JB, Kim JM, Chung BH, Kim JK, Kong JM.

Int Urol Nephrol. 2012 Oct;44(5):1549-57. doi: 10.1007/s11255-012-0169-1. Epub 2012 Apr 15.

PMID:
22528582
19.

ABO-incompatible kidney transplantation using antigen-specific immunoadsorption and rituximab: a 3-year follow-up.

Genberg H, Kumlien G, Wennberg L, Berg U, Tydén G.

Transplantation. 2008 Jun 27;85(12):1745-54. doi: 10.1097/TP.0b013e3181726849.

PMID:
18580466
20.

Impact of rituximab therapy for treatment of acute humoral rejection.

Kaposztas Z, Podder H, Mauiyyedi S, Illoh O, Kerman R, Reyes M, Pollard V, Kahan BD.

Clin Transplant. 2009 Jan-Feb;23(1):63-73. doi: 10.1111/j.1399-0012.2008.00902.x.

PMID:
19200217
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk